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The  antimetabolite six-mercaptopurine  (6-MP)  is  a  powerful immunosup- 
pressive drug. In experimental animals it depresses the synthesis of circulating 
antibodies (1), inhibits delayed hypersensitivity (2), and retards the rejection of 
allografts (3).  On  the basis  of these findings, the  treatment of a  variety of 
immunological diseases  and  attempts  to  delay the rejection of human ailo- 
grafts have been undertaken with 6-MP or its derivates, thioguanine and aza- 
thioprine (4).  Increasing clinical experience with these agents indicates, how- 
ever,  that an incomplete understanding of how they act hampers their most 
effective use. For example, though it is often assumed that the clinical results 
obtained with 6-MP are due to suppression of immunity, other effects of this 
antimetabolite, such as inhibition of inflammation (5, 6), cannot be discounted. 
The purpose of this report is to describe an additional and paradoxical action 
of 6-MP, the enhancement of antibody synthesis. 
These experiments were prompted by the observation that 6-MP treatment 
can cause hypertrophy of lymphoid tissue (7).  In rabbits, hyperplasia of the 
spleen and lymph nodes appeared within 2 days after the last dose of a  1 wk 
course of 6-MP (10 mg/kg/day) and gradually diminished during the succeed- 
ing 3 wk. Five days after such a course of 6-MP the lymphoid hyperplasia was 
at its peak. The spleen and lymph nodes were grossly enlarged and on micro- 
scopic examination they were seen to contain many follicles with greatly en- 
larged germinal centers. Numerous primitive ceils  resembling hemocytoblasts 
were present. There were, however, no morphologic signs of antibody forma- 
tion: neither tingible bodies nor mature plasma cells were found (Fig. 1). 
In the following experiments, the immune responses of rabbits recovering 
from a 7 day course of 6-MP were tested and compared with antibody produc- 
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tion in animals given 6-MP according to several other schedules. A  wide range 
of effects on antibody synthesis, from marked enhancement  to profound sup- 
pression, was found. 
Materials and Methods 
AmimaSs.--Adult New Zealand white rabbits, obtained from a locai supplier, housed under 
standard conditions, and fed Purina Rabbit Chow and water ad lib. were used. 
Ant~gens.--Bovine gamma globulin (BGG,  Pentex) was dissolved in 0.15 tr NaC1 to the 
desired concentration. Im-labded BGG was prepared by  the  Helmkamp  procedure  (8). 
Aggregated BGG was prepared by heating a  solution of BGG in a water bath at 63°C for 
30 rain. 
Antibody Titration.--Bleedings were  obtained at frequent intervals, particularly during 
the early phases of the response, and antibody titrations were done by means of the tanned 
red blood cell technique (9). The results, which were reproducible within -4-1 serial dilution, 
were converted to log~ units for purposes of graphic presentation. IgM (19S) and IgG (7S) 
antibodies were discriminated on the basis of sensitivity to 2-mercaptoethanol (2-ME)  (10). 
We (11) previously showed that anti-BGG antibodies obtained from both normal and 6-MP- 
treated rabbits which were inhibited by 0.1 M 2-ME were found in the bottom layers of an 
ultracentrifuged sucrose gradient and in the first protein peak after chromatography of whole 
serum on Sephadex G-200. In contrast, antibodies insensitive to the action of 0.1 tr 2-ME were 
found in the upper layers of the gradient and in the second protein peak of chromatographed 
serum. In agreement with others (12, 13), the Larger, heavier 2-ME-sensitive antibodies were 
classified as IgM and the smaller, lighter 2-ME-resistant antibodies were termed IgG. 
The clearance from the circulating blood of la2Ltagged BGG was determined by measuring 
radioactivity of serum samples in a well-type scintillation counter according to methods pre- 
viously described (1). 
Six-Mercaptopurine.---6-MP was freshly prepared just before use by dissolving an appro- 
priate amount in 1.0 m NaOH, then diluting with 0.15 M saline to the desired concentration 
(10 rag/m1). Each animal received 1 ml of the dissolved drug per kg subcutaneously.  Regard- 
lees of timing schedules  (with reference to the day of antigen administration), all test rabbits 
received 10 mg/kg of 6-MP daffy for 1 wk. This dosage of the drug was not associated with 
overt signs of toxicity such as diarrhea and weight loss. 
RESULTS 
Three different schedules of 6-MP administration and three different levels of 
antigen dosage were studied systematically (Text-figs.  1,  2,  and 3).  Each  test 
animal was given 6 MP, 10 mg/kg/day for 7 days. Two, 5, or 20 days after the 
last injection of the drug they received a  single intravenous injection of either 
0.02,  2.0,  or  200  mg  of BGG.  Control  rabbits  were  given  only  the  antigen. 
There were thus nine groups of test animals and three groups of control rabbits. 
Each group comprised 4 to 8 animals. 
Two days after the last dose of a  1 wk course of 6-MP, enhancement of anti- 
body synthesis was found in rabbits given 0.02 mg and 2.0 mg of BGG, but not 
in the group which had received 200 mg of BGG (Text-fig. 1). A  dose of 0.02 
mg of BGG failed to evoke a  primary immune response in most of the control 
rabbits.  In  contrast,  a  brisk  antibody  response  was  elicited in  all  the  test 
animals given this dose of antigen.  Most of the hemagglutinating anti-BGG Q: 
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Tsx-r-FIG. 1. Antibody responses when BGG was given 2 days after the last dose of a  1 wk 
course of 6-MP. In this and succeeding charts, titers of control animals are shown by lines 
connected by closed circles; titers of 6-MP-treated rabbits are indicated by lines connected 
by open circles. The dose of antigen is shown above each vertical panel. In all instances, 
antigen was given intravenously on day 0. 
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TEXT-Fro, 2. Antibody responses when BGG was given 5 days after the last dose of a  1 wk 
course of 6-MP. See legend to Text-fig. 1. 
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TExT-FzG. 3. Antibody responses when BGG was given 20 days after the last dose of a  1 wk 
course of 6-MP.  See legend to Text-fig. 1. 
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antibodies produced by these rabbits was IgM. Rabbits given 2.0 mg of BGG 
2 days after the last dose of 6-MP also showed exaggerated antibody responses. 
In contrast to animals receiving the lower dosage of antigen, both the IgM and 
IgG responses were enhanced in this group of rabbits. 
Five days after the last dose of 6-MP, when lymphoid hypertrophy has been 
found to be at its peak (7),  all groups of test animals showed enhancement of 
the immune response  (Text-fig. 2).  This was particularly evident in rabbits 
given 0.02 and 2.0 mg of antigen. Enhancement of both IgM and IgG responses 
occurred in all groups. In animals receiving 0.02 and 2.0 mg of BGG there was 
a distinct shortening of the induction time (the period between antigen admini- 
stration  and  the  first appearance  of serum  antibody),  and  in  some rabbits 
circulating antibodies could be detected within 12 hours of antigen administra- 
tion. 
When antigen was administered 20 days after the last dose of 6-MP, un- 
equivocal enhancement of total antibody synthesis occurred only when 0.02 
mg of BGG was given (Text-fig. 3). Average peak titers of total antibodyin the 
group given 2.0 mg  of  BGG were  similar  in  both  test  and  control  groups 
(8.0  and  6.5  respectively),  but hemagglutinating IgG  antibodies  appeared 
earlier in the test group (average, 5.0 days) than in the control group (average, 
9.3 days). The average peak titer of IgM antibody was higher in the test group 
given 200 mg of BGG (7.0)  than in the corresponding control group (4.4). 
The following experiments were carried out in order to determine whether or 
not the processes of antigen capture and priming, important elements of the 
primary  immune  response,  are  involved  in  the  enhancement  of  antibody 
production by 6-MP. The delineation of antigen capture was attempted in two 
ways: measurement of the rate of clearance of II~-tagged BGG from the circu- 
lating blood, and of antibody production in response to a particulate antigen. 
Effects on the priming mechanism were examined by studies of the secondary 
response. 
The rates of clearance of I125-tagged BGG (total concentration of radioactive 
BGG plus carrier antigen, 2.0 mg/ml; each rabbit received an intravenous dose 
of 1.0 ml) were estimated in 4 normal rabbits and in 4 animals tested 5 days 
after the last dose of a  1 wk course of 6-MP, 10 mg/kg/day. The results were 
similar  in the two cases: the average time of appearance of the immune dear- 
ance phase was 7.5 days in control rabbits; in test animals it was 7.2 days. 
In the next experiment, heat-aggregated BGG was employed as the antigenic 
stimulus on the supposition that if the 6-MP treatment led to activation of the 
macrophage system, administration of this particulate form of antigen should 
lead to a  highly exaggerated immune response. Two groups of rabbits  were 
given 6-MP, 10 mg/kg/day for 7 days; 5 days after the last dose of 6-MP, one 
group received 1.0 ml of a  heat-aggregated suspension of BGG, calculated to 
contain 2.0 mg/ml. The other group was given 2 mg of BGG dissolved in saline. DEVENDRATHAN  CHANMOUGAN  AND  ROBERT  S.  SCHWARTZ  369 
The results are shown in Text-fig. 4. No additional enhancement of antibody 
synthesis was found in the rabbits given the particulate form of BGG. It may 
be noteworthy that the average  induction time in the group given  BGG in 
solution was 2.0 days and that in the rabbits receiving aggregated BGG was 
4.4 days. 
Possible effects of 6-MP on the priming mechanism were studied by examin- 
ing the secondary immune responses of normal rabbits and of rabbits whose 
primary {mmune response had been exaggerated  by pretreatment with 6-MP. 
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"IkxT-Fm. 4. Antibody responses when BGG was given either in solution or as a particulate 
suspension (heat-aggregated), 5 days after the last dose of a 1 wk course of 5-MP. 
Two control groups, one given two doses of 2.0 mg of BGG 6 weeks apart, the 
other challenged in the same way with two doses of 0.02 mg of BGG, were 
compared with two corresponding  test groups  which had received  their first 
antigenic challenge 5 days after the last dose of a 1 wk course of 6-MP. 6-MP 
was not given at any other time. The results are shown in Text-fig.  5. The 
secondary responses of test and control rabbits given two injections of 2.0 mg 
of BGG were virtually identical.  Antibody titers in test rabbits rechallenged 
with 0.02 mg of BGG were higher than those in the corresponding  controls. 
However, the drug-treated rabbits had an average titer of approximately 4 log2 
units of antibody at the time of the second stimulus, whereas the control rabbits 
had no detectable antibody. Since this value of 4 log~ units probably repre- 
sented a  steady state of antibody synthesis induced by the first injection of 370  ANTIBODY  SYNTHESIS 
antigen, it was subtracted from each of the values obtained in the drug-treated 
animals during the secondary response. This resulted in no difference between 
control and test groups. 
In the following experiments, the timing schedules of 6-MP which produced 
enhancement of antibody synthesis were compared with four other schedules 
of 6-MP administration. The only variable was the timing of drug administra- 
tion with respect to the day of antigenic challenge. The first dose of the 7 day 
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T~x-r-Fz6. 5.  Secondary immune responses in  control and  6-MP-treated  rabbits.  The 
drug-treated animals (open circles) were given a 1 wk course of 6-MP beginning 12 days before 
the first antigenic challenge. The dose of antigen used in both the primary and secondary 
immunizations is indicated at the top of the panels. In the left panel, the line connected by 
dosed triangles represents the titers of the 6-MP-trcated rabbits minus 4 log2 units of antibody 
(see text). 
course of 6-MP was moved forward progressively from 12 days before the anti- 
genic challenge to 6  days after administration of BGG. Text-fig. 6  shows the 
results when  2.0 mg of BGG were used;  a  similar series of experiments was 
carried out in rabbits challenged with 0.02 mg of BGG and is shown in Text-fig. 
7.  With either dose of antigen, maximum enhancement of antibody synthesis 
was found when  6-MP was given on days  --12  to  --15  (the day of antigen 
administration counting as 0); maximum suppression of the immune response 
occurred when the first dose of 6-MP coincided with the day of antigen adminis- DEVENDRATHAN  CHANMOUGAN  AND ROBERT S. SCHWARTZ  3~I 
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tradon.  Intermediate degrees of enhancement  or suppression were  seen with 
the other schedules. 
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DISCUSSION 
The results of these experiments demonstrate that a wide spectrum of effects, 
ranging from increased antibody formation to complete inhibition of the im- 
mune  response, can  be elicited by treatment  with 0-MP.  Suppression of the DEVENDRATHAN  CH.ANMOIIGAN AND  ROBERT  S.  SCRWARTZ  373 
primary immune response, the first of these effects to be recognized, hinges on a 
series of important early events which are activated by the contact of lymphoid 
tissue with antigen (4). In contrast, the enhancement of antibody formation by 
6-MP depends upon effects initiated by the drug before the encounter between 
lymphoid tissue and antigen. 
Any explanation of the adjuvant effect of 6-MP must take into consideration 
two apparently divergent observations: (a) the main effect of the drug is cyto- 
toxicity, and (b) pronounced  lymphoid hyperplasia can occur after treatment 
with this antimetabolite. We propose that nucleic acids released from cells in- 
jured by 6-MP could account for both the hyperplasfic lymphoid tissue and the 
enhanced production of antibodies. In the ensuing paragraphs we shall analyze 
the following interpretation of the adjuvant effect of 6-MP: (a) The 1 wk course 
of drug treatment led to the death of various cells. (b) On discontinuation of the 
suppressive drug, nucleic acids derived from injured cells initiated stimulation 
of lymphoid  tissue.  The result was hyperplasia of lymph nodes and  spleen, 
which reached a peak 5 days after the last dose of 6-MP.  (c) Introduction of 
antigen at that time was associated with a rapid and maximal response by the 
expanded and activated lymphoid tissue. 
Six-MP affects cells by blocking the conversion of inosinic  acid to adenylic 
acid (14).  Since adenylic acid is essential  in the biosynthesis of nucleic acids, 
proteins, carbohydrates, and lipids,  the specific biochemical lesion induced by 
6-MP leads to widespread and ultimately fatal disorders in cellular metabolism. 
It is reasonable to assume that,  following  injury by this antimetabolite,  the 
contents of dying and dead cells, including  nucleic acids,  are released into the 
local environment.  The importance of nucleic acids is stressed because these 
cell constituents can enhance the production of antibodies (15, 16). To the best 
of our knowledge, no other cell breakdown product has this property.  Since 
enzymatically digested DNA and RNA also enhance antibody synthesis (15- 
18), hydrolysis by local nucleases would not necessarily abolish any adjuvant 
effects of nucleic acids deposited in situ. 
Following  their  release  from  6-MP-injured  tissue,  nucleic  acids  or  their 
degradation products could be taken up by living  cells. It is known that  the 
DNA of lymphocytes is reutilized by cells of intestinal crypts and regenerating 
liver (19) and that polynucleotides can be incorporated directly into lympho- 
cytes (20) and strain L cells (21). Even entire chromosomes can be taken up by 
mammalian  cells  (22).  Nucleic acids or nucleic acid digests could, after their 
incorporation into cells, have profound effects, since they are capable of stimu- 
lating cell division (23), protein synthesis (24),  and  enhanced growth of cells 
(25, 26). 
An increase only in the total mass of lymphoid tissue in 6-MP-treated rabbits 
should have resulted in enhancement of antibody synthesis at each dosage of 
antigen used. This was not the case; in the drug-treated rabbits large doses of 374  ANTIBODY  SYNTHESIS 
antigen  provoked  only  slightly  more  antibody  synthesis  than  small  doses. 
Text-fig. 8 shows an experiment in which antigen doses differing by 5 orders of 
magnitude  evoked  similar  peak  titers  of antibody  in  6-MP-treated  rabbits. 
Thus,  in addition  to hyperplasia,  a  qualitative  change involving a  specialized 
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TExT-FzG. 8. The "masking"  of the adjuvant effect of 6-MP by a large dose of antigen. 
2 X  10  -~ mg of BGG is barely immunogenie in normal rabbits  (closed triangles); in 6-MP- 
treated animals it evokes a brisk immune  response (open trlangels) wlgch is nearly equal to 
that provoked by challenge with a large dose of antigen, 2 X  10  a mg of BGG (open circles). 
This dose may represent the maximum stimulus which can be delivered in a single intravenous 
injection. Since the lymphoid tissue is probably already responding maximally, 6-MP treat- 
ment cannot further augment antibody synthesis when such large doses of antigen are used 
(closed circles). The rapid reduction of antibody titers in the drug-treated  rabbits challenged 
with 2 X  10  -2 mg BGG (open triangles) probably  reflects loss of antigen by catabolism or 
other means. The pattern of this response suggests that the persistence of antigen, at least for 
some days, is important in sustaining antibody synthesis. 
lymphoid cell seems likely.  Several findings might indicate  the nature  of this 
cell:  (a)  There  was no evidence  of accelerated  clearance  of antigen  from the 
circulating  blood;  (b)  challenge  with  heat-aggregated  (particulate)  BGG  was 
not associated with enhancement above that found with BGG in solution;  (c) 
the secondary responses  of rabbits  whose primary responses  were augmented 
by 6-MP were normal; (d) large numbers of hemocytoblasts were present in the 
lymphoid tissues at the time of maximum enhancement. The first two observa- 
tions suggest  that systems involved in  the  capture  of antigen  (macrophages) DEVENDRATHAN  CHANMOUGAN  AND  ROBERT  S. SCHWARTZ  375 
were not influenced  by the 6-MP treatment. The third finding means that im- 
munological  memory was not affected. These three groups of results suggest the 
participation of a cell capable of direct stimulation by antigen and lacking a 
memory mechanism. Such a cell might be the hemocytoblast (27, 28), the type 
of cell actually observed in large numbers 5 days after the last dose of a 1 wk 
course of 6-MP. 
The experimental results concerned with antigen dosage seem consistent with 
a  clonal  selection theory of antibody formation. It is conceivable that nucleic 
acids from dead cells could stimulate  a  precursor cell  (lymphocyte?) to dif- 
ferentiate into a hemocytoblast in a manner analogous to the action of phyto- 
hemagglutinin  (29).  Assuming  that  a  nearly  synchronous transformation  of 
precursor lymphocytes to antigen-sensitive hemocytoblasts occurred, an intra- 
venous dose of 0.02 mg of BGG would define the maximum responsiveness of the 
"anti-BGG clone." Higher doses of antigen did not result in substantially more 
antibody synthesis because of the physical limits of that clone. 
In addition to 6-MP, many other cytotoxic agents are capable of enhancing 
antibody synthesis,  including  X-irradiarion  (30,  31),  5-fluoro-2-deoxyuridine 
(32), uracil mustard (33), cyclophosphamide (33), cortisone (34), penicillamine 
(35),  colchicine  (36),  and endotoxin (37).  In mice,  whole body X-irradiarion, 
prednisone,  methotrexate,  and  6-MP markedly aggravated  allogenic  disease 
(38), an immunologic  disorder caused by the graft versus host reaction. It has 
been previously proposed that the adjuvant effects of some of these agents are 
mediated by nucleic acids released from injured cells (32, 39, 40). The observa- 
tions that nucleic acids and nucleic acid digests can restore antibody formation 
in X-irradiated animals (15, 16, 41) and in 6-MP-treated rabbits (42), that the 
nuclear contents of spleen cells accelerate allogenic disease (43), and that oligo- 
nucleorides enhance antibody formation in mice (17, 18) are all consistent with 
this interpretation of the adjuvant effects of cytotoxic agents. 
The generality of the phenomenon of increased antibody synthesis resulting 
from treatment with agents also possessing  immunosuppressive and cytotoxic 
effects has obvious clinical significance. The "triggering" of autolmmune hemo- 
lyric anemia in patients with lymphosarcoma or chronic lymphocytic leukemia 
by X-rays and alkylating agents has already been described (44). Whether or 
not the elucidation of this bimodal effect in experimental animals  will affect 
current  trends  in  immunosuppressive  therapy  will  naturally  depend  on  the 
results of clinical  investigations. 
SlY~rARY 
The administration of 6-MP to rabbits led to either suppression or enhance- 
ment of antibody production, depending on when the drug was given in relation 
to the antigenic challenge.  Maximum enhancement of antibody synthesis was 
found when a small dose of BGG was administered 5 days after the last dose of a 376  ANTIBODY  SYNTHESIS 
1 wk course of 6-MP. There were no indications that the macrophage system or 
immunological  memory  was  affected in  animals  with  augmented  antibody 
synthesis. It was proposed that enhancement of antibody production by 6-MP 
was due to nucleic acids released from cells killed or injured by the drug. It 
was suggested that lymphocytes incorporating these nucleic acids were trans- 
formed into specialized cells capable of direct and immediate stimulation by 
antigen  and  lacking  immunological memory  (hemocytoblasts).  A  relatively 
small dose of antigen was apparently capable of stimulating all the hemocyto- 
blasts representing a given clone, with the result that large mounts of antibody 
rapidly  appeared  in  the  serum. 
The authors wish to acknowledge the valuable technical assistance of Miss Jane Reins- 
borough. 
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EXPLANATION  OF PLATE 31 
FlOS. 1 a to d.  Histologic appearances of rabbit lymph nodes 5 days after the last 
dose of a  1 wk course of 6-MP, 10 mg/kg daffy. 
FIG.  1  a. Low power view,  showing  numerous  follicles with  enlarged  germinal 
centers.  Hematoxylin and eosin stain.  ×45. 
FI~. 1 b. Numerous blast cells in the medulla, characteristically grouped around 
and sometimes filling lymphatic channels  (arrows).  Giemsa stain.  ×  450. 
FI~S.  1 c and d.  Additional examples of blast cells (dassified  as hemocytoblasts). 
X 450. ¢, Giemsa stain; d, hematoxylin and eosin stains. THE JOURNAL  OF EXPERIMENTAL  MEDICINE  VOL. 124  PLATE 31 
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